Patents by Inventor Gesine Hansen

Gesine Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952631
    Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 9, 2024
    Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Daniel Todt, Sibylle Haid, Martin Wetzke, Gesine Hansen, Chris Lauber, Lars Kaderali, Thomas Pietschmann
  • Publication number: 20200283848
    Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.
    Type: Application
    Filed: October 9, 2018
    Publication date: September 10, 2020
    Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Daniel TODT, Sibylle HAID, Martin WETZKE, Gesine HANSEN, Chris LAUBER, Lars KADERALI, Thomas PIETSCHMANN
  • Patent number: 8865414
    Abstract: The invention provides a combination of reagents as a test kit containing a detection conjugate having a binding portion and a reagent for deactivating of the fluorochrome portion by interaction with the linker. The binding portion especially is an antibody portion. The detection conjugate has a fluorochrome portion connected to the antibody portion, and a linker connected to the fluorochrome portion, wherein the linker comprises an oligonucleotide. The fluorochrome portion can be deactivated by hydrolysis of the linker or by specific hybridization of a quencher having an oligonucleotide to the linker.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: October 21, 2014
    Assignee: Medizinische Hochschule Hannover
    Inventors: Christian Hennig, Gesine Hansen
  • Publication number: 20120129193
    Abstract: There is provided a carrier substrate for nonspecific immobilization of living bacterial and/or eukaryotic cells, especially of animal cells, which can be present as single cells, cell agglomerates or tissue sections. The surface of the carrier substrate is provided at least sectionally with a layer having or consisting of oligonucleic acids, preferably having ribonucleic acids covalently coupled to the carrier substrate, e.g. RNA, preferably single-stranded or double-stranded DNA.
    Type: Application
    Filed: October 27, 2009
    Publication date: May 24, 2012
    Applicant: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Christian Hennig, Gesine Hansen
  • Publication number: 20110311966
    Abstract: The invention provides a combination of reagents as a test kit containing a detection conjugate having a binding portion and a reagent for deactivating of the fluorochrome portion by interaction with the linker. The binding portion especially is an antibody portion. The detection conjugate has a fluorochrome portion connected to the antibody portion, and a linker connected to the fluorochrome portion, wherein the linker comprises an oligonucleotide. The fluorochrome portion can be deactivated by hydrolysis of the linker or by specific hybridization of a quencher having an oligonucleotide to the linker.
    Type: Application
    Filed: December 17, 2009
    Publication date: December 22, 2011
    Applicant: Medizinische Hochschule Hannover
    Inventors: Christian Hennig, Gesine Hansen